Fluoretiq progress to EIS funding
Deepbridge are pleased to announce that Fluoretiq Ltd, which is attempting to revolutionise the way bacteria is identified, have now joined the Deepbridge Life Sciences EIS portfolio.
REQUEST E-APPLICATION FORM | 01244 746000 | Log in
Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.
Investments in unquoted companies carry high risks and investors could lose all funds invested. No established market exists for the trading of shares in private companies, making it difficult to sell shares. The value of tax reliefs depend on personal circumstances and may be subject to change in the future. Investors are encouraged to take independent legal, tax and financial advice before considering an investment.
By clicking below, you confirm that you are an FCA authorised firm or individual and agree to be directed to our website, which is for FCA authorised firms and individuals only. Persons who do not meet this classification should leave this page.
If you are not a professional financial adviser, please contact the Deepbridge Investor Relations Team on 01244 746000 or by email at enquiries@deepbridgecapital.com.
Deepbridge are pleased to announce that Fluoretiq Ltd, which is attempting to revolutionise the way bacteria is identified, have now joined the Deepbridge Life Sciences EIS portfolio.
Deepbridge are pleased to announce that Hand Hygiene Solutions Ltd, which is intending to develop an automated software solution to aim to improve the collection of robust hand hygiene compliance data, have now joined the Deepbridge Life Sciences EIS portfolio.
Andrew Aldridge, Partner and Head of Marketing at Deepbridge, recently wrote a blog for the financial reporter discussing how keeping a year-round focus on tax benefits your clients
Deepbridge are pleased to announce that Manchester Biotech Ltd, which is supporting scientists to use bioprinting, liquid handling and 3D cell culture to develop new technologies that aim to improve patient lives, have now joined the Deepbridge Life Sciences EIS portfolio.
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
What are the key risks?
1. You could lose all the money you invest
2. You are unlikely to be protected if something goes wrong
3. You won’t get your money back quickly
4. Don’t put all your eggs in one basket
5. The value of your investment can be reduced
If you are interested in learning more about how to protect yourself, visit the FCA’s website here. [https://www.fca.org.uk/investsmart]